GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE

Amol S. Rangnekar, M.D., M.S.

Department of Medicine

MedStar Georgetown University Hospital

Transplant Institute

3800 Reservoir Rd. NW, 2 PHC

Washington, DC 20007

(202) 444-3700 (phone)

(877) 680-8192 (fax)

amol.s.rangnekar@gunet.georgetown.edu

1. PERSONAL INFORMATION

A. Education:

Undergraduate:                          Northwestern University, Evanston, IL, USA, 1998-2001, B.A., Economics

Medical Education:              Feinberg School of Medicine, Northwestern University, Chicago, IL, USA,

2001-2005, M.D.

Graduate Education:              University of Michigan, Ann Arbor, MI, USA, 2010-2011, M.S.,

Health & Health Care Research

Internship:              Montefiore Medical Center, Internal Medicine, Bronx, NY, USA, 2005-2006

Residency:              University of Michigan Hospital, Internal Medicine, Ann Arbor, MI, USA, 2006-2008

Fellowship:              University of Michigan Hospital, Gastroenterology, Ann Arbor, MI, USA, 2009-2012

Fellowship:              New York Presbyterian Hospital, Columbia University, Transplant Hepatology, New York, NY, USA, 2012-2013

B. Professional Experience:

Associate Professor of Medicine, Georgetown University Medical Center, Washington, DC, USA,

2022-present

Assistant Professor of Medicine, Georgetown University Medical Center, Washington, DC, USA,

2013-2022

Clinical Lecturer in Medicine, University of Michigan Hospital, Ann Arbor, MI, USA, 2008-2009

C. Licensure:

State: District of Columbia

License No: MD 041665

Initial Date: 6/28/13

Renewal/Expiration Date:  12/31/24

State: Virginia

License No: 010125805

Initial Date: 2/28/14

Renewal/Expiration Date:  2/28/26

State: Maryland

License No: D0080477

Initial Date: 10/1/15

Renewal/Expiration Date:  9/30/25

D. Certification:

Board Certification: Internal Medicine

Date of Certification: 8/2008

Date of Re-certification: 8/2028

Sub-Specialty Board: Gastroenterology

Date of Certification: 10/2012

Date of Re-certification: 10/2022

Sub-Specialty Board: Transplant Hepatology

Date of Certification: 10/2014

Date of Re-certification: 10/2024

E. Languages Spoken:

English (fluent)

2. RESEARCH AND SCHOLARLY ACTIVITIES

A. Publications:

i. Original Papers in Refereed Journals

Alhaqqan D, Khiew YC, Dadashzadeh M, He AR, Thomas A, Rangnekar A. Current Transplantation Reports 2024;11(3):1-9

Kiparizoska S, Nguyen V, Rangnekar AS. Graft-vs-host disease in a liver transplant patient with COVID-19 infection. ACG Case Rep J 2023;10(1):e00971.

Johnson-Laghi, KA, Woo, SM, Zafar Z, Fernansez S, Desale S, Robertazzi S, Smith C, Thomas A, Lalos A, Georgia SJ, Jenkins ML, Faust TW, Fishbein T, Satoskar R, Rangnekar AS and Hsu CC. Alcohol-associated liver disease predicts increased post-liver transplant opioid use. Clin Transplant 2022;36(12):e14811.

Samala N, Wang RY, Sungyoung A, Kara Balla A, Dakhoul L, Alter HJ, Ghabril M, Lucey M, Rangnekar AS, Reddy KR, Ghany MG. Rates of HEV infection among solid-organ transplant recipients in the Unites States. J Viral Hep 2022 Dec;29912):1134-42.

Rich NE, Yang JD, Perumalswami PV, Alkhouri N, Jackson, W, Parikh ND, Mehta N, Salgia R, Duarte-Rojo A, Kulik L, Rakoski M, Said A, Oloruntoba O, Ioannou GN, Hoteit MA, Moon AM, Rangnekar AS, Eswaran SL, Zheng E, Jou JH, Hanje J, Pillai A, Hernaez R, Wong R, Scaglione S, Samant H, Kapuria D, Chandna S, Rosenblatt R, Ajmera V, Frenette CT, Satapathy SK, Mantry P, Jalal P, John BV, Fix OK, Leise M, Lindenmeyer CC, Flores A, Patel N, Jiang ZG, Latt N, Dhanasekaran R, Odewole M, Kagan S, Marrero JA, Singal AG. Provider attitudes and practice patterns for direct-acting antiviral therapy in patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol 2020 Apr;18(4):974-83.

Singal AG, Rich NE, Mehta N, Branch A, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld JJ, John BV, Frenette C, Mantry P, Rangnekar AS, Oloruntoba O, Leise M, Jou JH, Bhamidimarri KR, Kulik L, Ioannou GN, Huang A, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo A, Salgia R, Eswaran S, Jalal P, Flores A, Satapathy SK, Kagan S, Gopal P, Wong R, Parikh ND, Murphy CC. Direct-acting antiviral therapy for HCV infection is associated with increased survival in patients with a history of hepatocellular carcinoma. Gastroenterology 2019 Nov;157(5):1253-63.

Dao A, Abidian M, Lestrange A, Mattar M, Rangnekar A, et al. Oral vancomycin induces and maintains remission of ulcerative colitis in the subset of patients with associated primary sclerosing cholangitis. Inflamm Bowel Dis 2019;25(7):e90-e91.

Singal AG, Rich NE, Mehta N, Branch A, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld JJ, John BV, Frenette C, Mantry P, Rangnekar AS, Tran T, Samant H, Dhanasekaran, Dhanasekaran R, Duarte-Rojo A, Salgia R, Eswaran S, Jalal P, Flores A, Satapathy SK, Wong R, Huang A, Misra S, Schwartz M, Mitrani R, Nakka S, Noureddine W, Ho C, Konjeti V, Dao A, Nelson K, Delarosa K, Rahim U, Mavuram M, Xie JJ, Murphy CC, Parikh ND. Direct-acting antiviral therapy not associated with recurrence of hepatocellular carcinoma in a multicenter North American cohort study. Gastroenterology 2019;156(6):1683-92.

Di Poto C, He S, Varghese RS, Zhao Y, Ferrarini A, Su S, Karabala A, Redi M, Mamo H, Rangnekar AS, Fishbein TM, Kroemer AH, Tadesse MG, Roy R, Sherif ZA, Kumar D, Ressom HW. Identification of race-associated metabolite biomarkers for hepatocellular carcinoma in patients with liver cirrhosis and hepatitis C virus infection. PLoS One 2018 Mar;13(3):e0192748.

Levine I, Rangnekar AS, Tokayer AZ. Low frequency of polyps in colonic regions with diverticulosis. Int J Colorectal Dis 2017 Nov;32(11):1597-1602.

Chakrabarti A, Osborne N, Rangnekar AS, Mathur AK. The effect of hospital characteristics on racial/ethnic variation in cirrhosis mortality.  J Racial Ethn Health Disparities 2017 Apr;4(2):243-51.

Fontana RJ, Ellerbe C, Durkalski VE, Rangnekar A, Reddy RK, Stravitz T, McGuire B, Davern T, Reuben A, Liou I, Fix O, Ganger DR, Chung RT, Schilsky M, Han S, Hynari LS, Sanders C, Lee WM. Two-year outcomes in initial survivors with acute liver failure: results from a prospective, multicentre study. Liver Int. 2015 Feb;35(2):370-80.

Rangnekar AS, Ellerbe C, Durkalski V, McGuire BM, Lee WM, Fontana RJ. Quality of life is significantly impaired in long-term survivors of acute liver failure and particularly in acetaminophen-overdose patients. Liver Transpl. 2013 Sept;19(9):991-1000.

Rangnekar AS and Fontana RJ. IL-28B polymorphisms and the response to antiviral therapy in HCV genotype 2 and 3 varies by ethnicity: a meta-analysis. J Viral Hepat. 2013 Jun;20(6):377-84.

Rangnekar AS and Fontana RJ. Meta-analysis: IL-28B genotype and sustained viral clearance in HCV genotype 1 patients. Aliment Pharmacol Ther. 2012 Jul;36(2):104-14.

Rangnekar AS and Fontana RJ. Managing drug-drug interactions with boceprevir and telaprevir. Clinical Liver Disease. 2012 Apr;1(2):36-40.

Elmunzer BJ, Padhya KT, Lewis JJ, Rangnekar AS, Saini SD, Eswaran SL, Scheiman JM, Pagani FD, Haft JW, Waljee AK. Endoscopic findings and clinical outcomes in ventricular assist device recipients with gastrointestinal bleeding. Dig Dis Sci. 2011 Nov;56(11):3241-6.

Rangnekar AS, Lammert F, Igolnikov A, Green RM. Quantitative trait loci analysis of mice administered the methionine-choline deficient dietary model of experimental steatohepatitis. Liver Int. 2006 Oct;26(8):1000-1005.

ii. Reviews or Editorials in Refereed Journals

Gildea DT, Woo SM, O’Connor CE, Rangnekar AS. COVID-19-asscoiated liver injury. Hepatic Medicine: Evidence and Research 2023;15:1-9

Gildea DT, Alhaqqan D, Johnson K, Rangnekar AS. Bouveret syndrome in a cirrhotic patient. Cureus 2022;14(12):e32270.

Woo, SM, Kimchy AV, Lynette M, Sequeira C, Dorris S, He AR, Rangnekar AS. Immunotherapy use prior to liver transplant in patients with hepatocellular carcinoma. Curr Oncol 2022;29(12):9813-25.

Duong N, Sadowski B, Rangnekar AS. The impact of frailty, sarcopenia, and malnutrition on liver transplant outcomes. Clin Liver Dis 2021 May;17(4):271-6.

Sadowski B, Baba T, Rangnekar AS. Pro: Cardiac catheterization is the optimal strategy for cardiovascular risk stratification in this patient. Clin Liver Dis 2021 Jan;17(1):33-6.

Dao A, Rangnekar AS. Steroids for severe alcoholic hepatitis: more risk than reward? Clin Liver Dis 2019 Jan;12(6):151-3.

Rangnekar AS and Fontana RJ. An update on drug induced liver injury. Minerva Gastroenterol Dietol. 2011 Jun;57(2):213-29.

Rangnekar AS and Chey WD. The FODMAP diet for irritable bowel syndrome: food fad or roadmap to a new treatment paradigm? Gastroenterology. 2009 Jul;137(1):383-386.

Rangnekar AS and Chey WD. Methylnaltrexone: a new treatment for an old problem. Gastroenterology. 2008 Nov;135(5):1792-1794.

Rangnekar AS and Chey WD. Review: tissue transglutaminase test is almost as accurate as endomysial antibody test for diagnosis of coeliac disease. Evid Based Med. 2007 Feb;12(1):24.

iii. Books or Chapters in Books (indicate if refereed)

Mohanraj B, Rangnekar AS, Timpone JG. Chapter 3: Infections in liver transplantation. Principles and Practice of Transplant Infectious Diseases. 2019.

iv. Abstracts for Conference papers and posters

Gildea DT, Woo S, Waterman A, Rios Perez C, Johnson K, Rangnekar AS, Hsu C. Early alcohol relapse in liver transplant recipients associated with significant hepatic fibrosis. Liver Meeting 2023

Gildea DT, Woo S, Johnson K, Hsu C, Rangnekar AS. Extended post-liver transplant opioid use associated with early alcohol recidivism. DDW 2023

Patel P, Rangnekar A, Hsu C. Risk factors for renal replacement therapy in patients with alcoholic hepatitis after liver transplant.  Liver Meeting 2021

Woo S, Zafar Z, Rangnekar A, Hsu, C. Unemployment associated with higher risk of post-transplant alcohol recidivism. Digestive Disease Week 2021

Desphande N, Kareff SA, Rangnekar A. So itchy: an atypical presentation of Budd-Chiari syndrome. Society of Hospital Medicine Meeting 2021

Higley C, Yan W, Ahmed S, Dao A, Murphy ME, Patti A, Mattar M, Rangnekar AS. Therapeutic benefits of oral vancomycin in patients with PSC and UC. Hepatology 2020.

Clinton J, Sadowski B, Rangnekar AS. Improved peri-operative outcomes in liver transplant with portal vein thrombosis after TIPS. Hepatology 2020

Johnson K, Rangnekar AS, Robertazzi SE, et al. Predictors of prolonged post-liver transplant opiate use in patients with alcoholic liver disease. Hepatology 2020

Boustani C, Stone B, Rangnekar A. Drug induced liver injury and concurrent hemophagocytic lymphohistiocytosis after lamotrigine exposure. Am J Gastroenterol 2020

Stone B, Clinton J, Patti A, Rangnekar A. Acute HEV infection causing elevated liver enzymes in a kidney transplant recipient. Am J Gastroenterol 2020

Singal AG, Rich NE, Mehta N, Branch A, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld JJ, John BV, Frenette C, Mantry P, Rangnekar AS, et al. Direct-acting antiviral therapy is associated with improved survival in patients with a history of hepatocellular carcinoma: a multicenter North American cohort study. Hepatology 2019 Oct;70(S1):130A-31A.

Johnson K, Rangnekar AS, et al. Alcoholic liver disease predicts increased post-liver transplant opioid use. Hepatology 2019 Oct;70(S1):707A.

McDermott C, Ertreo M, Fernandez S, Rangnekar AS, et al. Hepatic adenomatosis increases risk of hepatic adenoma bleeding. Hepatology 2019 Oct;70(S1):1217A.

Dao A, Abidian MM, Lestrange A, Mattar M, Rangnekar A, Charabaty A.  Oral vancomycin induces and maintains remission of ulcerative colitis in subset of patients with associated primary sclerosing cholangitis (UC-PSC).  Gastroenterology 2019 May;156(6: Suppl 1):S-28.

Parpia T, Gergen D, Timpone J, Javaid B, Rangnekar AS. Use of rifaximin or spontaneous bacterial peritonitis prophylaxis does not increase the risk of early multi-drug resistant infections after liver transplant. Hepatology 2017;66(S1):896A.

Parpia T, Gergen D, Rangnekar A, et al. Multi-drug-resistant organism (MDRO) infections in liver transplant recipients 30 days post-transplant. Open Forum Infect Dis 2017 Fall;4(Suppl 1):S709.

Barnhill M, Rangnekar A. Resolution of jaundice in a patient with primary biliary cholangitis on obeticholic acid. Am J Gastroenterol 2017 Oct;112:S1192.

Nolan A, Onwudiwe C, Satoskar R, Rangnekar A, et al. Hepatitis B immunoglobulin withdrawal in HBsAg positive liver transplant patients. Am J Transplant 2016;16 (Suppl 3)

Khan R, Albugeary M, Rangnekar AS. Oral vancomycin effect in primary sclerosing cholangitis. Am J Gastroenterol.  2015 Oct;110(S1):S393.

Javaid AI, Hahn KJ, Kwok RM, Albugeaey M, Rangnekar AS, et al. A fatal cause of fever and pancytopenia in a patient with ulcerative colitis treated with azathioprine.  Am J Gastroenterol. 2015 Oct;110(S1):S389.

Morales SJ, Hahn KJ, Kwok RM, Albugeaey M, Virk MS, Rangnekar AS, et al.  A case of acute liver failure following initiation of valproic acid. Am J Gastroenterol 2015 Oct;110(S1):S348.

Rangnekar AS, Ellerbe C, Durkalski V, McGuire BM, et al. Quality of life is significantly impaired in long-term survivors of acute liver failure (ALF) and particularly in acetaminophen overdose patients. Hepatology. Oct 2012;56(S1):956A.

Fontana RJ, Ellerbe C, Durkalski V, Rangnekar AS, et al. 2-year survival is significantly lower in spontaneous survivors with non-acetaminophen acute liver failure versus liver transplant recipients. Hepatology. Oct 2012;56(S1):191A.

Rangnekar AS and Fontana RJ. IL-28B genotype is strongly associated with spontaneous clearance of HCV infection in both Caucasians and African-Americans: a meta-analysis. Gastroenterology. 2012 May;142(5 Supp 1):S928.

Rangnekar AS and Fontana RJ. IL-28B genotype is associated with RVR and SVR in some patients with HCV genotype 2 and 3: a meta-analysis. Hepatology. 2011 Oct;54(S1):814A-815A.

Rangnekar AS and Fontana RJ. IL28B genotype and the likelihood of SVR in Caucasian and African-American patients with HCV genotype 1: a meta-analysis. Gastroenterology. 2011 May;140(5 Supp 1):S948-949.

Rangnekar AS, Saad RJ, Morgan DM, Fenner D, Chey WD. Do abnormalities on testing for dyssynergic defecation correlate with abdominal pain and bloating in constipated patients? Gastroenterology. 2009 May;136(5 Supp 1):A217.

Rangnekar AS, Morgan D, Knechtges P, Saad RJ, Fenner D, Morris AM, Chey WD. Complaints suggestive of irritable bowel syndrome are common in patients with puborectalis dyssynergia: an under-recognized overlap syndrome. Gastroenterology. 2008 Apr;134(4 Supp 1):A423.

Rangnekar AS, Tokayer AZ. Low frequency of colon polyps in association with diverticulosis.  Am J Gastroenterol. 2007 Sep;102(s2):S562-563.

Rangnekar AS, Brandt LJ, Tokayer AZ. An analysis of the prevalence of diverticulosis in association with colon adenocarcinoma. Am J Gastroenterol. 2006 Sept;101(s2):S558-559.

B. Research/Funding:

i. Current Active             

Agency: Ocelot Bio

Identifying Number: IRB Study 00006083

Title of Project: A Multi-center, Randomized, Placebo-Controlled, Double-Blind Adaptive Dose-Ranging Study to Assess Safety and Efficacy of Intravenous OCE-205 in Adults Diagnosed with Cirrhosis with Ascites who have Developed Hepatorenal Syndrome-Acute Kidney Injury (HRS-AKI)

Dates of Project Period: 2023

Corresponding PI: Amol Rangnekar, MD

Role on Project: Principal Investigator

Agency: University of Michigan; Genentech

Identifying Number: IRB Study 00004079

Title of Project: Noninvasive Assessment of Esophageal Varices in Patients with Unresectable Hepatocellular Carcinoma

Dates of Project Period: 2021-2023

Corresponding PI: Amol Rangnekar, MD

Role on Project: Principal Investigator

Identifying Number: IRB 2018-1168

Title of Project: TARGET-HBV

Dates of Project Period: 2018-Present

Corresponding PI: Coleman Smith, MD

Role on Project: Co-Investigator

Identifying Number: IRB 2017-0198

Title of Project: TARGET-NASH

Dates of Project Period: 2017-Present

Corresponding PI: Coleman Smith, MD

Role on Project: Co-Investigator

Identifying Number: IRB 2017-0365

Title of Project: Unleash the Potential of Immunomonitoring in Transplantation (UPIT)

Dates of Project Period:              2017-present

Corresponding PI: Alexander Kroemer, MD, PhD

Role on Project: Co-Investigator

Identifying Number: IRB 2018-0716

Title of Project: Benefits of oral vancomycin for ulcerative colitis and primary sclerosing cholangitis in adults

Dates of Project Period:              2018-present

Corresponding PI: Amol Rangnekar, MD

Role on Project: Principal Investigator

Agency: NIH                           

Identifying Number: IRB 2015-0702

Title of Project: Seroprevalence of Hepatitis E in Organ Transplant Subjects

Dates of Project Period:              2015-present

Corresponding PI: Amol Rangnekar, MD

Role on Project: Study Co-investigator, site Principal Investigator

Identifying Number: 00002138

Title of Project: Impact of TIPS on OLT Outcomes

Dates of Project Period:              2020-present

Corresponding PI: Amol Rangnekar, MD

Role on Project: Principal Investigator

Agency: NIH

Identifying Number: 2017-1523

Title of Project: Comparison of Outcomes in Transplantation for Acute Alcoholic Hepatitis: American Consortium of Early Liver Transplantation for Alcoholic Hepatitis (ACCELERATE-AH) versus Outcomes of Patients Transplanted for Alcohol Cirrhosis

Dates of Project Period:              2017-present

Corresponding PI: Christine Hsu, MD

Role on Project: Co-Investigator

Identifying Number: 2018-0717

Title of Project: Tumor Associated Collagen Signature in Hepatocellular Carcinoma

Dates of Project Period:              2018-present

Corresponding PI: Christine Hsu, MD

Role on Project: Co-investigator

Agency: PCORI                           

Identifying Number: 2015-0317

Title of Project: HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network

Dates of Project Period:              2015-2017

Corresponding PI: Coleman Smith, MD

Role on Project: Co-investigator

Agency: Tobira Therapeutics, Inc.                           

Identifying Number: 2017-0516

Title of Project: AURORA: Phase 3 Study for the Efficacy and Safety of CVC for the Treatment of Liver Fibrosis in Adults with NASH

Dates of Project Period:              2017-present

Corresponding PI: Coleman Smith, MD

Role on Project: Co-investigator

Identifying Number: 2018-0773

Title of Project: Statin Therapy to Reduce Disease Progression from Liver Cirrhosis to Cancer

Dates of Project Period:              2018-present

Corresponding PI: Coleman Smith, MD

Role on Project: Co-investigator

Agency: Bristol Myers Squibb                           

Identifying Number: 2018-0963

Title of Project: A Phase 2B randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of BMS-986036 (PEG-FGF21) in Adults with Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis

Dates of Project Period:              2018-present

Corresponding PI: Coleman Smith, MD

Role on Project: Co-investigator

Agency: Bristol Myers Squibb                           

Identifying Number: 2018-0964

Title of Project: A Phase 2B randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of BMS-986036 (PEG-FGF21) in Adults with Nonalcoholic Steatohepatitis (NASH) and Compensated Liver Cirrhosis

Dates of Project Period:              2018-present

Corresponding PI: Coleman Smith, MD

Role on Project: Co-investigator

Identifying Number: 2016-1083

Title of Project: Multi-Drug Resistant Organism (MDRO) Infections in Liver Transplant Recipients in the 30 Day Post-Operative Period: A Retrospective Study

Dates of Project Period:              2016-present

Corresponding PI: Joseph Timpone, MD

Role on Project: Co-investigator

Identifying Number: 2011-482

Title of Project: Prevention and Treatment of Amatoxin Induced Hepatic Failure with Intravenous Silibinin (Legalon® SIL): An Open Multicenter Clinical Trial (Phase II / III)

Dates of Project Period:              2011-present

Corresponding PI: Rohit Satoskar, MD

Role on Project: Co-investigator

Title of Project: A Phase 3, Randomized Multicenter Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis

Corresponding PI: Coleman Smith, MD

Role on Project: Co-investigator

ii. Previous

Agency: Enanta                           

Identifying Number: 2016-1102

Title of Project: A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability, and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTI) in Adults with Nonalcoholic Steatohepatitis (NASH)

Dates of Project Period:              2016-2018

Corresponding PI: Amol Rangnekar, MD

Role on Project: Principal Investigator

Agency: AbbVie                           

Identifying Number: 2017-1507

Title of Project: Outcomes in Patients with Hepatocellular Carcinoma

Dates of Project Period:              2017-2018

Corresponding PI: Amol Rangnekar, MD

Total Direct plus Indirect Costs over all years of award:  $2700

Role on Project: Co-investigator

Identifying Number: 2014-1085

Title of Project: A Retrospective and Prospective Review of the Use of Direct Acting Antiviral Agents (DAA) in the Treatment of Post Kidney and Liver Transplant Recurrent Hepatitis C

Dates of Project Period:              2018-2019

Corresponding PI: Coleman Smith, MD

Role on Project: Co-investigator

Agency: Conatus                           

Identifying Number: 2015-0312

Title of Project: A Multicenter, Double-Blind, Randomized Trial of IDN- 6556 in Subjects Who had Hepatitis C Virus (HCV) Reinfection and Liver Fibrosis or Cirrhosis following Orthotopic Liver Transplantation for Chronic HCV Infection and Who Subsequently Achieved a Sustained Virologic Response Following anti-HCV Therapy

Dates of Project Period:              2015-2017

Corresponding PI: Coleman Smith, MD

Role on Project: Co-investigator

Agency: NGM Biopharmaceuticals                           

Identifying Number: 2016-0267

Title of Project: A Phase 2, Randomized, Double Bind, Placebo-Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients with Primary Sclerosing Cholangitis (PSC)

Dates of Project Period:              2016-2018

Corresponding PI: Coleman Smith, MD

Role on Project: Co-investigator

Agency: Gilead             

Identifying Number: 2016-0316

Title of Project: A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks in Subjects with Chronic Genotype 3 HCV Infection and Cirrhosis

Dates of Project Period:              2016-2018

Corresponding PI: Coleman Smith, MD

Role on Project: Co-investigator

Agency: Gilead             

Identifying Number: 2016-0317

Title of Project: A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 12 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting Antiviral-Experienced Subjects with Chronic HCV Infection who Have Not Received an NS5A Inhibitor

Dates of Project Period:              2016-2018

Corresponding PI: Coleman Smith, MD

Role on Project: Co-investigator

Agency: Gilead             

Identifying Number: 2016-0672

Title of Project: A Pilot Study to Assess Safety, Tolerability, and Efficacy of Sofosbuvir and Ledipasvir for Hepatitis C Treatment in HIV/HCV Coinfected Subjects Pre or Post Liver Transplant

Dates of Project Period:              2016-2018

Corresponding PI: Coleman Smith, MD

Role on Project: Co-investigator

Agency: Genfit

Identifying Number: 2016-0901

Title of Project: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with Nonalcoholic Steatohepatitis (NASH) and fibrosis

Dates of Project Period:              2016-2018

Corresponding PI: Coleman Smith, MD

Role on Project: Co-investigator

Agency: Gilead

Identifying Number: 2017-0315

Title of Project: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis           

Dates of Project Period:              2017-2019

Corresponding PI: Coleman Smith, MD

Role on Project: Co-investigator

Agency: Gilead

Identifying Number: 2017-0388

Title of Project: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH)

Dates of Project Period:              2017-2019

Corresponding PI: Coleman Smith, MD

Role on Project: Co-investigator

Agency: AbbVie

Identifying Number: 2017-0464

Title of Project: A Single Arm, Open-label Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment Naïve Adults with Chronic Hepatitis C Virus (HCV) Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis

Dates of Project Period:              2017-2019

Corresponding PI: Coleman Smith, MD

Role on Project: Co-investigator

Identifying Number: 2017-0469

Title of Project: Procurement of Blood Samples from Subjects with Diagnosed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) for Use in the Development of a Liver Fibrosis Test

Dates of Project Period:              2017-2019

Corresponding PI: Coleman Smith, MD

Role on Project: Co-investigator

Agency: AbbVie

Identifying Number: 2017-0464

Title of Project: A Phase 3b, Multi-Center, Randomized, Open-Label, Pragmatic Study of Glecaprevir/Pibrentasvir (G/P) +/- Ribavirin for GT1 Subjects with Chronic Hepatitis C Previously Treated with an NS5A Inhibitor + Sofosbuvir Therapy

Dates of Project Period: 2017-2019

Corresponding PI: Coleman Smith, MD

Role on Project: Co-investigator

Agency: Conatus

Identifying Number: 2017-1116

Title of Project: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects with Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis

Dates of Project Period: 2017-2019

Corresponding PI: Coleman Smith, MD

Role on Project: Co-investigator

Agency: Mallinckrodt

Identifying Number: 2013-1300

Title of Project: Multicenter, Randomized Phase 2B Study to Evaluate the Efficacy, Safety and Tolerability of OCR-002 (ornithine phenylacetate) in Hospitalized Patients with Cirrhosis and Associated Hyperammonemia with an Episode of Hepatic Encephalopathy (STOP-HE)

Dates of Project Period:              2013-2016

Corresponding PI: James Lewis, MD

Role on Project: Co-investigator

Agency: Vital Therapies, Inc.

Identifying Number: 2012-1510

Title of Project: A Randomized, Open-Label, Multicenter, Controlled Study to Assess Safety and Efficacy of ELAD in Subjects with Alcohol-Induced Liver Decompensation (AILD)

Dates of Project Period:              2012-2015

Corresponding PI: Rohit Satoskar, MD

Role on Project: Co-investigator

Agency: Vital Therapies, Inc.

Identifying Number: 2012-1082

Title of Project: A Randomized, Open-Label, Multicenter, Controlled Study to Assess Safety and Efficacy of ELAD in Subjects with Severe Acute Alcoholic Hepatitis (AAH) and Lille Score Failure

Dates of Project Period:              2012-2015

Corresponding PI: Rohit Satoskar, MD

Role on Project: Co-investigator

Agency: Merck

Identifying Number: 2014-1147

Title of Project: A Phase III Double Blind Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Treatment-Naïve Subjects with Chronic HCV GT1, GT4, and GT6 Infection with Inherited Blood Disorders with and without HIV Co-Infection

Dates of Project Period:              2014-2017

Corresponding PI: Rohit Satoskar, MD

Role on Project: Co-investigator

Agency: Vital Therapies, Inc.

Identifying Number: 2015-1053

Title of Project: An Open-Label, Multicenter, Historically-Controlled Study to Assess Safety and Efficacy of ELAD in Subjects with Acute Liver Failure (ALF)

Dates of Project Period: 2015-2018

Corresponding PI: Rohit Satoskar, MD

Role on Project: Co-investigator

Agency: Mallinckrodt

Identifying Number: 2016-0666

Title of Project: A Multi-center, Randomized, Placebo-Controlled, Double-Blind Study to Confirm Efficacy and Safety of Terlipressin in Subjects with Hepatorenal Syndrome Type 1

Dates of Project Period: 2016-2019

Corresponding PI: Rohit Satoskar, MD

Role on Project: Co-investigator

Georgetown-Howard Universities Center for Clinical and Translational Science

Grant #UL1TR000101, NIH

Seroprevalence of Hepatitis E in Organ Transplant Subjects

2016

Clinical & Translational Science Award

Michigan Institute for Clinical & Health Research

University of Michigan

2010

Training Grant in Gastrointestinal Epidemiology

University of Michigan

Grant #T32 DK62708-01, NIDDK

C. Invited Lectures:

Lecture, MedStar GI APP Bootcamp, July 2024

Lecture, DC5 Consortium, University of Maryland, November 2023

Lecture, DC5 Consortium, University of Maryland, November 2021

Lecture, Department of Medicine Grand Rounds, Virginia Hospital Center, Arlington, VA, November 2021

Lecture, MedStar Georgetown Transplant Institute Symposium, Washington, DC, September 2021

Lecture, MedStar Georgetown Transplant Institute Academic Conference, Washington, DC, February 2021

Lecture, DC Critical Care Fellows’ Boot Camp, Washington, DC, July 2020

Lecture, MedStar Georgetown Update on Pancreaticobiliary Diseases, Washington, DC, February 2020

Lecture, MedStar Georgetown University Hospital Division of Critical Care Lecture Series, Washington, DC, February 2020

Lecture, Department of Medicine Grand Rounds, University of Maryland Prince George’s Hospital Center, Cheverly, MD, November 2019

Lecture, MedStar Georgetown Transplant Institute Symposium, Bethesda, MD, September 2019

Lecture, DC Critical Care Fellows’ Boot Camp, Washington, DC, July 2019

Lecture, MedStar Georgetown Updates in Inflammatory Bowel Diseases Meeting, Tysons, VA, May 2019

Lecture, MedStar Georgetown Transplant Institute Symposium, Bethesda, MD, May 2018

Lectures, AASLD Clinical Hepatology Update, Austin, TX, May 2018

Lecture, MedStar Georgetown University Hospital Internal Medicine Residency Lecture Series, Washington, DC, February 2018

Lecture, MedStar Georgetown Transplant Institute Academic Conference, Washington, DC, December 2017

Panel Discussion, AASLD Liver Meeting, Washington, DC, October 2017

Lecture, MedStar Georgetown University Hospital, Gastroenterology Fellowship Core Curriculum, Washington, DC, September 2017

Lecture, Advances in Liver Diseases and Transplantation course, Bethesda, MD, April 2017

Lecture, Advances in Liver Diseases and Transplantation course, Bethesda, MD, April 2016

Lecture, MedStar Georgetown University Hospital, Interventional Radiology Fellowship Lecture Series, Washington, DC, September 2017

Lecture, DC Critical Care Fellows’ Boot Camp, Washington, DC, July 2015

Lecture, MedStar Georgetown Transplant Institute Academic Conference, Washington, DC, April 2015

Lecture, MedStar Georgetown University Hospital, Gastroenterology Fellowship Core Curriculum, Washington, DC, September 2014

Lecture, DC Critical Care Fellows’ Boot Camp, Washington, DC, July 2014

Case Discussion, DC Gastroenterology CME Meeting, Washington, DC, May 2014

D. Editorships, Editorial Boards, and Reviewing Activities

Reviewer, Liver Transplantation, 2015-2020

Reviewer, Digestive Diseases and Sciences, 2019

Reviewer, Clinical and Translational Gastroenterology, 2020

Reviewer, Clinical Transplantation, 2020

Reviewer, Cureus, 2021

3. TEACHING, MENTORING, AND ADVISING

A. Teaching Activities

i. Medical School Courses

Name and Course Number: University of Michigan Medical School M2 Gastroenterology Sequence

Role: Small group leader

Number of Direct Contact Hours: 20

Year(s) Taught: 1

Number of Students: 15

ii. Medical School Clerkships

Name of Clerkship: Internal Medicine - Hepatology

Role: Attending physician (clinical and teaching attending)

Number of Direct Contact Hours: 280 hours per year

Year(s) Taught: 4

Number of Students/Fellows: 15 students, 16 residents, 16 fellows per year

Overall Evaluation Score:

Average number of Clinical Fellows you train per year = 21

Average number of Residents you train per year = 30

Average number of Medical students you train per year = 15

B. Mentoring:

Mentor: Amol Rangnekar, MD

Name of Mentee: Daniel Gildea, MD

Dates of Mentorship: July 2021-present

Outcomes: Accepted presentations, manuscript in progress, application for gastroenterology fellowship

Mentor: Amol Rangnekar, MD

Name of Mentee: Krystina Johnson, MD

Dates of Mentorship: July 2018-present

Outcomes: Accepted presentations, manuscript in submission, accepted to gastroenterology fellowship

Alcoholic liver disease predicts increased post-liver transplant opioid use (Liver Meeting, November 2019)

Mentor: Amol Rangnekar, MD

Name of Mentee: Alexander Dao, MD

Dates of Mentorship: December 2017-present

Outcomes: Publications (see below), oral presentation at national meeting, currently in gastroenterology fellowship

Dao A, Abidian M, Lestrange A, Mattar M, Rangnekar A, et al. Oral vancomycin induces and maintains remission of ulcerative colitis in the subset of patients with associated primary sclerosing cholangitis. Inflamm Bowel Dis 2019;25(7):e90-e91.

Dao A, Rangnekar AS. Steroids for severe alcoholic hepatitis: more risk than reward? Clin Liver Dis 2019 Jan;12(6):151-3.

Dao A, Abidian MM, Lestrange A, Mattar M, Rangnekar A, Charabaty A.  Oral vancomycin induces and maintains remission of ulcerative colitis in subset of patients with associated primary sclerosing cholangitis (UC-PSC).  Gastroenterology 2019 May;156(6: Suppl 1):S-28.

Mentor: Amol Rangnekar, MD

Name of Mentee: Tarina Parpia, MD

Dates of Mentorship: July 2016-2019

Outcomes: Publications (see below), manuscript in submission, poster presentations at national meetings, current fellow in infectious diseases at University of Virginia Hospital

Parpia T, Gergen D, Timpone J, Javaid B, Rangnekar AS. Use of rifaximin or spontaneous bacterial peritonitis prophylaxis does not increase the risk of early multi-drug resistant infections after liver transplant. Hepatology 2017;66(S1):896A.

Parpia T, Gergen D, Rangnekar A, et al. Multi-drug-resistant organism (MDRO) infections in liver transplant recipients 30 days post-transplant. Open Forum Infect Dis 2017 Fall;4(Suppl 1):S709.

4. SERVICE

A. University Service:

i. Department

Program Director, Transplant Hepatology Fellowship, 2019-present

Associate Program Director, Transplant Hepatology Fellowship, 2018-2019

Committee Member, Internal Medicine Residency Clinical Competency Committee, 2014-present

B. MedStar or Hospital Service

Medical Director, Living Donor Liver Transplantation, MedStar Georgetown University Hospital, 2019

Committee Member, Council for Associate and Patient Safety, MedStar Georgetown University Hospital 2014-2018

Committee Member, Division of Gastroenterology Education Committee, University of Michigan Hospital, 2011-2012

Committee Member, Medical Procedures Unit QI Committee, University of Michigan Hospital, 2009-2011

C. Professional Service:

Review Board Member, UNOS National Liver Review Board, 2019-present

Committee Member, AASLD Fundamentals of Liver Disease Committee, 2021-2024

Committee Member, AASLD Training and Workforce Committee, 2012-2015

5. HONORS AND AWARDS

Interdisciplinary Collaboration Award, MedStar Georgetown University Hospital, 2017

Advanced Transplant Hepatology Fellowship Award, American Association for the Study of Liver Diseases, 2012

Chief Fellow, University of Michigan Hospital Division of Gastroenterology, 2011

Hoyt Scholarship, Feinberg School of Medicine, Northwestern University, 2002

Honors Program in Medical Education, Northwestern University, 1998

6. PROFESSIONAL SOCIETY MEMBERSHIP

American Association for the Study of Liver Diseases, 2011-present